Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
DexCom Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | DexCom Inc. inventory turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | DexCom Inc. receivables turnover ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023. |
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | DexCom Inc. working capital turnover ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | DexCom Inc. number of days of inventory outstanding deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | DexCom Inc. number of days of receivables outstanding deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023. |
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | DexCom Inc. operating cycle deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Inventory Turnover
DexCom Inc., inventory turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Cost of sales | 351,700) | 324,900) | 278,900) | 273,900) | 275,400) | 246,700) | 230,700) | 225,600) | 203,300) | 178,000) | 161,100) | 169,800) | 160,500) | 167,700) | 148,600) | 153,500) | 149,400) | 129,900) | 111,700) | 115,200) | 98,100) | 88,900) | 65,500) | |||||||
| Inventory | 498,600) | 421,100) | 366,000) | 306,700) | 311,000) | 339,500) | 342,200) | 357,300) | 351,300) | 319,300) | 289,700) | 234,700) | 200,700) | 165,300) | 141,900) | 119,800) | 120,400) | 117,900) | 101,100) | 70,700) | 55,200) | 46,200) | 51,600) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Inventory turnover1 | 2.47 | 2.74 | 2.94 | 3.35 | 3.15 | 2.67 | 2.45 | 2.15 | 2.03 | 2.10 | 2.28 | 2.76 | 3.14 | 3.75 | 4.10 | 4.55 | 4.20 | 3.86 | 4.09 | 5.20 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 2.71 | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | 3.59 | 3.47 | 3.27 | 2.99 | 2.99 | 2.71 | 2.56 | 2.92 | 3.07 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 29.58 | 28.53 | 30.04 | 26.13 | 30.87 | 32.34 | 34.32 | 31.58 | 37.54 | 36.13 | 36.50 | 32.70 | 37.84 | 36.30 | 38.13 | 36.70 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 16.34 | 16.48 | 15.15 | 14.05 | 14.46 | 14.64 | 13.60 | 13.52 | 13.49 | 13.48 | 12.57 | 11.88 | 12.43 | 13.03 | 12.68 | 12.06 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | 2.98 | 2.90 | 2.84 | 2.64 | 2.49 | 2.18 | 2.22 | 2.30 | 2.30 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | 2.43 | 2.24 | 2.20 | 2.10 | 2.23 | 2.34 | 2.35 | 2.37 | 2.44 | 2.35 | 2.39 | 2.42 | 2.53 | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Inventory turnover
= (Cost of salesQ3 2023
+ Cost of salesQ2 2023
+ Cost of salesQ1 2023
+ Cost of salesQ4 2022)
÷ Inventory
= (351,700 + 324,900 + 278,900 + 273,900)
÷ 498,600 = 2.47
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | DexCom Inc. inventory turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Receivables Turnover
DexCom Inc., receivables turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Accounts receivable, net | 785,700) | 750,600) | 636,800) | 713,300) | 564,100) | 560,800) | 544,500) | 514,300) | 529,100) | 483,500) | 443,400) | 428,500) | 370,000) | 296,500) | 300,700) | 286,300) | 234,900) | 217,300) | 204,700) | 226,700) | 169,800) | 162,000) | 123,900) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Receivables turnover1 | 4.33 | 4.26 | 4.75 | 4.08 | 4.95 | 4.77 | 4.72 | 4.76 | 4.38 | 4.49 | 4.57 | 4.50 | 4.92 | 5.79 | 5.32 | 5.16 | 5.75 | 5.62 | 5.51 | 4.55 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | 6.64 | 6.61 | 6.58 | 6.13 | 5.40 | 5.70 | 6.12 | 6.06 | 5.88 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 10.53 | 11.44 | 11.65 | 11.79 | 11.94 | 11.27 | 11.30 | 11.91 | 11.23 | 11.48 | 11.32 | 12.32 | 11.14 | 11.68 | 11.33 | 13.04 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | 20.66 | 18.93 | 18.81 | 17.39 | 19.72 | 18.91 | 18.04 | 16.74 | 18.20 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 55.60 | 68.53 | 30.60 | 55.25 | 56.74 | 26.54 | 27.18 | 45.69 | 42.91 | 32.51 | 35.43 | 66.78 | 64.58 | 31.30 | 33.43 | 60.97 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | 7.30 | 7.90 | 7.38 | 6.96 | 6.75 | 7.32 | 8.56 | 8.73 | 6.94 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | 5.51 | 5.35 | 5.21 | 5.73 | 6.22 | 4.97 | 5.05 | 5.20 | 4.91 | 5.22 | 5.29 | 5.28 | 5.00 | — | — | — | |||||||
| UnitedHealth Group Inc. | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | 20.07 | 19.60 | 18.53 | 16.35 | 19.86 | 20.63 | 19.62 | 16.73 | 20.32 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Receivables turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Accounts receivable, net
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 785,700 = 4.33
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | DexCom Inc. receivables turnover ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023. |
Working Capital Turnover
DexCom Inc., working capital turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current assets | 4,698,400) | 5,002,900) | 3,767,400) | 3,668,800) | 3,398,500) | 3,808,700) | 3,746,600) | 3,684,400) | 3,656,200) | 3,474,200) | 3,445,100) | 3,424,800) | 3,237,100) | 3,033,000) | 1,995,700) | 1,969,400) | 1,815,700) | 1,744,200) | 1,690,800) | 1,699,500) | 914,100) | 836,000) | 729,300) | |||||||
| Less: Current liabilities | 1,678,600) | 2,069,700) | 1,865,000) | 1,839,300) | 900,500) | 807,000) | 711,400) | 720,800) | 734,900) | 600,700) | 604,100) | 614,100) | 506,400) | 400,100) | 342,800) | 360,200) | 322,400) | 288,200) | 235,400) | 222,400) | 193,900) | 170,800) | 125,100) | |||||||
| Working capital | 3,019,800) | 2,933,200) | 1,902,400) | 1,829,500) | 2,498,000) | 3,001,700) | 3,035,200) | 2,963,600) | 2,921,300) | 2,873,500) | 2,841,000) | 2,810,700) | 2,730,700) | 2,632,900) | 1,652,900) | 1,609,200) | 1,493,300) | 1,456,000) | 1,455,400) | 1,477,100) | 720,200) | 665,200) | 604,200) | |||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Working capital turnover1 | 1.13 | 1.09 | 1.59 | 1.59 | 1.12 | 0.89 | 0.85 | 0.83 | 0.79 | 0.76 | 0.71 | 0.69 | 0.67 | 0.65 | 0.97 | 0.92 | 0.90 | 0.84 | 0.77 | 0.70 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | 3.87 | 3.98 | 4.02 | 3.99 | 4.06 | 4.52 | 5.02 | 6.84 | 6.64 | — | — | — | — | — | — | — | |||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | 7.23 | 6.79 | 6.67 | 5.38 | 6.39 | 5.98 | 5.40 | 6.81 | 6.11 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 9.72 | 9.34 | 8.98 | 10.27 | 10.54 | 9.53 | 9.27 | 8.67 | 7.47 | 7.38 | 7.61 | 7.42 | 6.04 | 6.14 | 6.91 | 7.19 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | 1.22 | 1.17 | 1.03 | 0.88 | 0.77 | 0.80 | 0.88 | 1.23 | 1.23 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | 2.15 | 2.02 | 2.00 | 2.44 | 2.48 | 2.03 | 2.13 | 2.16 | 2.26 | 2.54 | 2.30 | 2.24 | 2.32 | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Working capital turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Working capital
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 3,019,800 = 1.13
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | DexCom Inc. working capital turnover ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023. |
Average Inventory Processing Period
DexCom Inc., average inventory processing period calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Inventory turnover | 2.47 | 2.74 | 2.94 | 3.35 | 3.15 | 2.67 | 2.45 | 2.15 | 2.03 | 2.10 | 2.28 | 2.76 | 3.14 | 3.75 | 4.10 | 4.55 | 4.20 | 3.86 | 4.09 | 5.20 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average inventory processing period1 | 148 | 133 | 124 | 109 | 116 | 137 | 149 | 170 | 180 | 174 | 160 | 132 | 116 | 97 | 89 | 80 | 87 | 95 | 89 | 70 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 135 | 139 | 132 | 118 | 108 | 113 | 109 | 102 | 105 | 111 | 122 | 122 | 135 | 142 | 125 | 119 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 12 | 13 | 12 | 14 | 12 | 11 | 11 | 12 | 10 | 10 | 10 | 11 | 10 | 10 | 10 | 10 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 22 | 22 | 24 | 26 | 25 | 25 | 27 | 27 | 27 | 27 | 29 | 31 | 29 | 28 | 29 | 30 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 183 | 166 | 162 | 161 | 155 | 139 | 130 | 122 | 126 | 129 | 138 | 147 | 167 | 164 | 159 | 159 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 190 | 183 | 174 | 166 | 161 | 153 | 148 | 150 | 163 | 166 | 174 | 164 | 156 | 155 | 154 | 150 | 156 | 153 | 151 | 144 | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.47 = 148
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | DexCom Inc. number of days of inventory outstanding deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Average Receivable Collection Period
DexCom Inc., average receivable collection period calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Receivables turnover | 4.33 | 4.26 | 4.75 | 4.08 | 4.95 | 4.77 | 4.72 | 4.76 | 4.38 | 4.49 | 4.57 | 4.50 | 4.92 | 5.79 | 5.32 | 5.16 | 5.75 | 5.62 | 5.51 | 4.55 | — | — | — | |||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average receivable collection period1 | 84 | 86 | 77 | 89 | 74 | 77 | 77 | 77 | 83 | 81 | 80 | 81 | 74 | 63 | 69 | 71 | 63 | 65 | 66 | 80 | — | — | — | |||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 59 | 56 | 53 | 52 | 52 | 58 | 59 | 55 | 55 | 55 | 60 | 68 | 64 | 60 | 60 | 62 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 35 | 32 | 31 | 31 | 31 | 32 | 32 | 31 | 32 | 32 | 32 | 30 | 33 | 31 | 32 | 28 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 20 | 19 | 22 | 19 | 19 | 19 | 22 | 18 | 19 | 19 | 21 | 19 | 19 | 20 | 22 | 20 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 7 | 5 | 12 | 7 | 6 | 14 | 13 | 8 | 9 | 11 | 10 | 5 | 6 | 12 | 11 | 6 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 51 | 50 | 53 | 55 | 51 | 51 | 56 | 50 | 46 | 49 | 52 | 54 | 50 | 43 | 42 | 53 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 70 | 67 | 62 | 64 | 63 | 63 | 63 | 66 | 68 | 70 | 64 | 59 | 73 | 72 | 70 | 74 | 70 | 69 | 69 | 73 | — | — | — | |||||||
| UnitedHealth Group Inc. | 21 | 19 | 25 | 20 | 20 | 22 | 23 | 18 | 19 | 20 | 22 | 18 | 18 | 19 | 22 | 18 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.33 = 84
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | DexCom Inc. number of days of receivables outstanding deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023. |
Operating Cycle
DexCom Inc., operating cycle calculation (quarterly data)
No. days
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | 148 | 133 | 124 | 109 | 116 | 137 | 149 | 170 | 180 | 174 | 160 | 132 | 116 | 97 | 89 | 80 | 87 | 95 | 89 | 70 | — | — | — | |||||||
| Average receivable collection period | 84 | 86 | 77 | 89 | 74 | 77 | 77 | 77 | 83 | 81 | 80 | 81 | 74 | 63 | 69 | 71 | 63 | 65 | 66 | 80 | — | — | — | |||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Operating cycle1 | 232 | 219 | 201 | 198 | 190 | 214 | 226 | 247 | 263 | 255 | 240 | 213 | 190 | 160 | 158 | 151 | 150 | 160 | 155 | 150 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 194 | 195 | 185 | 170 | 160 | 171 | 168 | 157 | 160 | 166 | 182 | 190 | 199 | 202 | 185 | 181 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 57 | 54 | 55 | 57 | 56 | 57 | 59 | 58 | 59 | 59 | 61 | 61 | 62 | 59 | 61 | 58 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 234 | 216 | 215 | 216 | 206 | 190 | 186 | 172 | 172 | 178 | 190 | 201 | 217 | 207 | 201 | 212 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 260 | 250 | 236 | 230 | 224 | 216 | 211 | 216 | 231 | 236 | 238 | 223 | 229 | 227 | 224 | 224 | 226 | 222 | 220 | 217 | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 148 + 84 = 232
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | DexCom Inc. operating cycle deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |